Insomnia: Recent advances in pharmacological management

Research output: Contribution to journalArticle

Abstract

The medications currently approved for the treatment of insomnia include 9 benzodiazepine receptor agonist (BZRA) hypnotics and the selective melatonin receptor agonist ramelteon. The BZRA hypnotics include the newer nonbenzodiazepine agents as well as benzodiazepines; the nonbenzodiazepine hypnotics tend to have shorter half-lives and are better at targeting sedation exclusively during the nighttime. The development of modified-release formulations of BZRA hypnotics, such as Zolpidem extended-release, has been a key innovation. These formulations allow both rapid and sustained release of the medication and may reduce the risk of next-day effects. Ramelteon has been shown to improve sleep during the early portion of the sleep period. Investigational agents include alternate-delivery formulations of BZRA compounds, which may help treat nighttime awakenings.

Original languageEnglish (US)
Pages (from-to)266-271
Number of pages6
JournalDrug Benefit Trends
Volume21
Issue number9
StatePublished - Oct 2009

Fingerprint

Sleep Initiation and Maintenance Disorders
GABA-A Receptors
Hypnotics and Sedatives
Pharmacology
Sleep
Melatonin Receptors
Benzodiazepines
ramelteon
Therapeutics

Keywords

  • Insomnia
  • Sleep disorders

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy

Cite this

Insomnia : Recent advances in pharmacological management. / Neubauer, David.

In: Drug Benefit Trends, Vol. 21, No. 9, 10.2009, p. 266-271.

Research output: Contribution to journalArticle

@article{4e9af3f3ed494d68a5d22aa4a6374c3c,
title = "Insomnia: Recent advances in pharmacological management",
abstract = "The medications currently approved for the treatment of insomnia include 9 benzodiazepine receptor agonist (BZRA) hypnotics and the selective melatonin receptor agonist ramelteon. The BZRA hypnotics include the newer nonbenzodiazepine agents as well as benzodiazepines; the nonbenzodiazepine hypnotics tend to have shorter half-lives and are better at targeting sedation exclusively during the nighttime. The development of modified-release formulations of BZRA hypnotics, such as Zolpidem extended-release, has been a key innovation. These formulations allow both rapid and sustained release of the medication and may reduce the risk of next-day effects. Ramelteon has been shown to improve sleep during the early portion of the sleep period. Investigational agents include alternate-delivery formulations of BZRA compounds, which may help treat nighttime awakenings.",
keywords = "Insomnia, Sleep disorders",
author = "David Neubauer",
year = "2009",
month = "10",
language = "English (US)",
volume = "21",
pages = "266--271",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "9",

}

TY - JOUR

T1 - Insomnia

T2 - Recent advances in pharmacological management

AU - Neubauer, David

PY - 2009/10

Y1 - 2009/10

N2 - The medications currently approved for the treatment of insomnia include 9 benzodiazepine receptor agonist (BZRA) hypnotics and the selective melatonin receptor agonist ramelteon. The BZRA hypnotics include the newer nonbenzodiazepine agents as well as benzodiazepines; the nonbenzodiazepine hypnotics tend to have shorter half-lives and are better at targeting sedation exclusively during the nighttime. The development of modified-release formulations of BZRA hypnotics, such as Zolpidem extended-release, has been a key innovation. These formulations allow both rapid and sustained release of the medication and may reduce the risk of next-day effects. Ramelteon has been shown to improve sleep during the early portion of the sleep period. Investigational agents include alternate-delivery formulations of BZRA compounds, which may help treat nighttime awakenings.

AB - The medications currently approved for the treatment of insomnia include 9 benzodiazepine receptor agonist (BZRA) hypnotics and the selective melatonin receptor agonist ramelteon. The BZRA hypnotics include the newer nonbenzodiazepine agents as well as benzodiazepines; the nonbenzodiazepine hypnotics tend to have shorter half-lives and are better at targeting sedation exclusively during the nighttime. The development of modified-release formulations of BZRA hypnotics, such as Zolpidem extended-release, has been a key innovation. These formulations allow both rapid and sustained release of the medication and may reduce the risk of next-day effects. Ramelteon has been shown to improve sleep during the early portion of the sleep period. Investigational agents include alternate-delivery formulations of BZRA compounds, which may help treat nighttime awakenings.

KW - Insomnia

KW - Sleep disorders

UR - http://www.scopus.com/inward/record.url?scp=72149101578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149101578&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:72149101578

VL - 21

SP - 266

EP - 271

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - 9

ER -